Published in J Cyst Fibros on December 28, 2012
Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention. ISME J (2015) 0.83
IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. J Cyst Fibros (2015) 0.81
Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis. Ann Am Thorac Soc (2015) 0.76
Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes. Pediatr Pulmonol (2017) 0.75
Progression of Lung Disease in Preschool Patients with Cystic Fibrosis. Am J Respir Crit Care Med (2016) 0.75
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med (2011) 8.73
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med (2010) 6.51
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med (2010) 6.23
Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med (2006) 6.10
Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med (2011) 5.61
Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med (2005) 5.51
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med (2015) 5.51
Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet (2011) 5.42
Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol (2005) 4.50
Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med (2011) 4.09
Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet (2008) 4.06
Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr (2007) 3.49
Tucson Children's Respiratory Study: 1980 to present. J Allergy Clin Immunol (2003) 3.41
Inner City Asthma Study: relationships among sensitivity, allergen exposure, and asthma morbidity. J Allergy Clin Immunol (2005) 3.38
Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study. Lancet (2007) 3.22
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax (2011) 2.84
Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma. J Allergy Clin Immunol (2004) 2.80
Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol (2006) 2.79
Wheezing and bronchial hyper-responsiveness in early childhood as predictors of newly diagnosed asthma in early adulthood: a longitudinal birth-cohort study. Lancet (2008) 2.70
Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA (2005) 2.56
Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol (2008) 2.56
Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest (2003) 2.54
Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997. Arthritis Rheum (2007) 2.27
Cost-effectiveness of a home-based environmental intervention for inner-city children with asthma. J Allergy Clin Immunol (2005) 2.22
Clinical screening of school children for polysomnography to detect sleep-disordered breathing--the Tucson Children's Assessment of Sleep Apnea study (TuCASA). J Clin Sleep Med (2005) 2.21
Persistence of asthma symptoms during adolescence: role of obesity and age at the onset of puberty. Am J Respir Crit Care Med (2004) 2.20
Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer (2006) 2.04
Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med (2007) 2.03
Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol (2006) 2.02
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97
Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr (2003) 1.97
Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S. Support Care Cancer (2008) 1.89
Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med (2002) 1.88
The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol (2002) 1.85
The Prevention of Early Asthma in Kids study: design, rationale and methods for the Childhood Asthma Research and Education network. Control Clin Trials (2004) 1.79
Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE. J Urol (2006) 1.77
Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatr Pulmonol (2010) 1.71
Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. J Urol (2007) 1.70
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med (2002) 1.70
Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA (2010) 1.69
Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer (2007) 1.68
Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatr Pulmonol (2002) 1.67
Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulmonol (2007) 1.67
Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol (2004) 1.65
Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol (2004) 1.64
Asthma control, adiposity, and adipokines among inner-city adolescents. J Allergy Clin Immunol (2010) 1.63
Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med (2006) 1.63
Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr (2008) 1.60
Effect of breastfeeding on lung function in childhood and modulation by maternal asthma and atopy. Am J Respir Crit Care Med (2007) 1.59
Cumulative cost pattern comparison of prostate cancer treatments. Cancer (2007) 1.57
Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology (2005) 1.57
Risk of current asthma among adult smokers with respiratory syncytial virus illnesses in early life. Am J Respir Crit Care Med (2014) 1.54
Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol (2004) 1.52
Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol (2005) 1.52
Impact of increased number of biopsies on the nature of prostate cancer identified. J Urol (2006) 1.50
Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc (2007) 1.49
Clinical outcomes associated with sleep-disordered breathing in Caucasian and Hispanic children--the Tucson Children's Assessment of Sleep Apnea study (TuCASA). Sleep (2003) 1.48
Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol (2007) 1.46
Early coronary revascularization diminishes the risk of ischemic stroke with acute myocardial infarction. Stroke (2006) 1.44
Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates. Arthritis Rheum (2004) 1.41
Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study. Clin Drug Investig (2008) 1.40
A framework for modelling fertility motivation in couples. Popul Stud (Camb) (2004) 1.39
Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol (2008) 1.39
Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol (2005) 1.37
Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros (2009) 1.35
Endometriosis fertility index: the new, validated endometriosis staging system. Fertil Steril (2010) 1.34
Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. J Pediatr (2009) 1.31
Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol (2008) 1.30
Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med (2007) 1.29
Learning in children and sleep disordered breathing: findings of the Tucson Children's Assessment of Sleep Apnea (tuCASA) prospective cohort study. J Int Neuropsychol Soc (2003) 1.27
Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio. Antimicrob Agents Chemother (2011) 1.26
Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer--data from CaPSURE. J Urol (2003) 1.25
Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. J Urol (2011) 1.25
Symptoms related to sleep-disordered breathing in white and Hispanic children: the Tucson Children's Assessment of Sleep Apnea Study. Chest (2003) 1.24
Airborne fungi in the homes of children with asthma in low-income urban communities: The Inner-City Asthma Study. J Allergy Clin Immunol (2004) 1.24
Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. Pediatr Pulmonol (2010) 1.23
Asthma outcomes workshop: overview. J Allergy Clin Immunol (2012) 1.22
Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual Life Res (2011) 1.21
Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma. J Allergy Clin Immunol (2009) 1.21
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol (2007) 1.19
Efficacy of osteopathic manipulation as an adjunctive treatment for hospitalized patients with pneumonia: a randomized controlled trial. Osteopath Med Prim Care (2010) 1.19
Birth characteristics and leukemia in young children. Am J Epidemiol (2002) 1.18